By Zoey Becker
AstraZeneca is back in the COVID-19 game with new data for its antibody cocktail, Evusheld. While it's existing authorizations cover the prophylactic setting, the latest results from the Big Pharma putsthe drug in contention as a treatment for patients with mild-to-moderate disease.
read more
By Heather Landi
Teladoc is facing a lawsuit alleging the company misled investors about the company’s business, operations and prospects as the virtual care company's stock price has plunged in the past year.
read more
By Conor Hale
The project aims to have CerTest’s CE-marked test operate on the BD MAX automated PCR system.
read more
By James Waldron
Innovent is catching up with the likes of Eli Lilly and Novo Nordisk as the Chinese pharma’s own obesity drug passes strong results in a phase 2 trial. A placebo-controlled trial of the drug, mazdutide, in 230 Chinese participants met the primary endpoint of a percentage change in baseline body weight at week 24.
read more
By Kevin Dunleavy
Tirzepatide weight loss data presented this week by Eli Lilly are so compelling that the drug and Novo Nordisk's Wegovy could in many circumstances replace sleeve bariatric and gastric bypass surgeries—often seen as last resorts for those who are morbidly obese. That is the belief of a key opinion leading obesity specialist who was consulted by SVB Securities.
read more
By Dave Muoio
An average 13.9% of hospitals’ total expenses went toward community benefits in 2019, according to a recent report from the American Hospital Association and Ernst & Young.
read more
By Andrea Park
A year after being laid to rest, the troubled HeartWare Ventricular Assist Device system is causing problems for Medtronic.
read more
By Angus Liu
Before the introduction of Keytruda, Merck & Co. wasn’t exactly a major oncology player. Now holding the world’s best-selling cancer drug, the New Jersey pharma looks to consolidate its leadership with more than 80 potential cancer approvals by 2028.
read more
By James Waldron
Moderna hopes that the successful readout from a phase 2/3 trial of its omicron-targeting COVID-19 shot means the booster will be ready for people’s arms by the late summer.
read more
By Anastassia Gliadkovskaya
A lack of implementation or compliance with public health measures "played a significant role" in mortality, which was likely driven by individual political beliefs.
read more
By Andrea Park
Ginkgo Bioworks has acquired certain assets from Bitome, which is developing machine learning technology to track how well individual cell lines are performing throughout the programming process.
read more
